Oramed Pharmaceuticals (ORMP) 10-K 29 Nov 17 2017 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Aug. 31, 2017	Nov. 28, 2017	Feb. 28, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	1,176,309
Trading Symbol	ORMP
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-K
Document Period End Date	Aug. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 56,748,843
Entity Common Stock, Shares Outstanding		14,306,100

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Aug. 31, 2017	Aug. 31, 2016
CURRENT ASSETS:
Cash and cash equivalents	$ 3,969	$ 3,907
Short-term deposits (note 2)	13,293	24,254
Marketable securities (note 3)	2,860	2,855
Restricted cash	16	16
Prepaid expenses and other current assets	159	198
Total current assets	20,297	31,230
LONG-TERM ASSETS:
Long-term deposits and investment (note 4)	16,232	11,043
Marketable securities (note 3c)	2,151	530
Amounts funded in respect of employee rights upon retirement	14	11
Property and equipment, net	18	16
Total long-term assets	18,415	11,600
Total assets	38,712	42,830
CURRENT LIABILITIES:
Accounts payable and accrued expenses	2,716	1,411
Deferred revenues	2,449	2,162
Related parties (note 11c)		48
Total current liabilities	5,165	3,621
LONG-TERM LIABILITIES:
Deferred revenues	13,837	12,604
Employee rights upon retirement	18	14
Provision for uncertain tax position (note 10e)	11	11
Other liabilities	443	390
Total long-term liabilities	14,309	13,019
COMMITMENTS (note 6)
STOCKHOLDERS' EQUITY:
Common stock, $ 0.012 par value (30,000,000 authorized shares as of August 31, 2017 and 2016; 13,668,530 and 13,183,425 shares issued and outstanding as of August 31, 2017 and 2016, respectively)	163	157
Additional paid-in capital	75,170	71,943
Accumulated other comprehensive income	401	106
Accumulated loss	(56,496)	(46,016)
Total stockholders' equity	19,238	26,190
Total liabilities and stockholders' equity	$ 38,712	$ 42,830

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 31, 2017	Aug. 31, 2016
Balance Sheets [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	13,668,530	13,183,425
Common stock, shares outstanding	13,668,530	13,183,425

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Income Statement [Abstract]
REVENUES	$ 2,456	$ 641
COST OF REVENUES (notes 6j, 6k)	187	490
RESEARCH AND DEVELOPMENT EXPENSES, NET	10,281	7,709	4,781
GENERAL AND ADMINISTRATIVE EXPENSES	2,759	2,452	2,602
OPERATING LOSS	10,771	10,010	7,383
FINANCIAL INCOME (note 9a)	792	474	168
FINANCIAL EXPENSES (note 9b)	101	93	18
LOSS BEFORE TAXES ON INCOME	10,080	9,629	7,233
TAXES ON INCOME (TAX BENEFIT) (note 10c)	400	1,335	(1)
NET LOSS FOR THE YEAR	10,480	10,964	7,232
UNREALIZED LOSS (GAIN) ON AVAILABLE FOR SALE SECURITIES	(295)	452	(106)
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)	(295)	452	(106)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 10,185	$ 11,416	$ 7,126
LOSS PER SHARE OF COMMON STOCK:
BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	$ 0.79	$ 0.87	$ 0.67
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER SHARE OF COMMON STOCK	13,309,372	12,624,356	10,820,465

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock		Additional paid-in capital	Accumulated other comprehensive income	Accumulated loss
BALANCE at Aug. 31, 2014	$ 20,793	$ 121		$ 48,040	$ 452	$ (27,820)
BALANCE, Shares at Aug. 31, 2014		10,103
SHARES, OPTIONS AND WARRANTS ISSUED FOR CASH, NET	9,713	$ 17		9,696
SHARES, OPTIONS AND WARRANTS ISSUED FOR CASH, NET, Shares		1,411
SHARES ISSUED FOR SERVICES	93		[1]	93
SHARES ISSUED FOR SERVICES, Shares		15
EXERCISE OF OPTIONS	8		[1]	8
EXERCISE OF OPTIONS, Shares		1
STOCK-BASED COMPENSATION	1,347		[1]	1,347
STOCK-BASED COMPENSATION, Shares		33
OTHER COMPREHENSIVE INCOME	106				106
NET LOSS	(7,232)					(7,232)
BALANCE at Aug. 31, 2015	24,828	$ 138		59,184	558	(35,052)
BALANCE, Shares at Aug. 31, 2015		11,563
SHARES ISSUED FOR SERVICES	101		[1]	101
SHARES ISSUED FOR SERVICES, Shares		14
ISSUANCE OF COMMON STOCK, NET	10,594	$ 14		10,580
ISSUANCE OF COMMON STOCK, NET, Shares		1,155
EXERCISE OF WARRANTS AND OPTIONS	1,449	$ 4		1,445
EXERCISE OF WARRANTS AND OPTIONS, Shares		350
STOCK-BASED COMPENSATION	634	$ 1		633
STOCK-BASED COMPENSATION, Shares		101
OTHER COMPREHENSIVE INCOME	(452)				(452)
NET LOSS	(10,964)					(10,964)
BALANCE at Aug. 31, 2016	26,190	$ 157		71,943	106	(46,016)
BALANCE, Shares at Aug. 31, 2016		13,183
SHARES ISSUED FOR SERVICES	72		[1]	72
SHARES ISSUED FOR SERVICES, Shares		10
ISSUANCE OF COMMON STOCK, NET	25		[1]	25
ISSUANCE OF COMMON STOCK, NET, Shares		3
EXERCISE OF WARRANTS AND OPTIONS	1,561	$ 4		1,557
EXERCISE OF WARRANTS AND OPTIONS, Shares		313
STOCK-BASED COMPENSATION	1,575	$ 2		1,573
STOCK-BASED COMPENSATION, Shares		159
OTHER COMPREHENSIVE INCOME	295				295
NET LOSS	(10,480)					(10,480)
BALANCE at Aug. 31, 2017	$ 19,238	$ 163		$ 75,170	$ 401	$ (56,496)
BALANCE, Shares at Aug. 31, 2017		13,668
[1]	Represents an amount of less than $1.

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (10,480)	$ (10,964)	$ (7,232)
Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation	5	4	4
Exchange differences and interest on deposits and held to maturity bonds	124	(163)	(20)
Stock-based compensation	1,575	634	1,347
Shares issued for services	72	101	93
Changes in operating assets and liabilities:
Prepaid expenses, other current assets and related parties	39	(71)	345
Accounts payable, accrued expenses and related parties	1,257	470	16
Deferred revenue	1,520	14,266	500
Liability for employee rights upon retirement	4	3	2
Provision for uncertain tax position		(15)	(1)
Other liabilities	53	390
Total net cash provided by (used in) operating activities	(5,831)	4,655	(4,946)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(7)	(9)	(1)
Purchase of short-term deposits	(3,557)	(7,010)	(3,673)
Purchase of long-term deposits	(17,230)	(22,274)	(17,452)
Purchase of held to maturity securities	(3,869)	(1,775)	(1,885)
Proceeds from sale of short-term deposits	26,551	14,160	19,701
Proceeds from maturity of held to maturity securities	2,417	900
Funds in respect of employee rights upon retirement	(3)	(2)	(2)
Total net cash provided by (used in) investing activities	4,302	(16,010)	(3,312)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, options and warrants - net of issuance costs	25	10,594	9,713
Proceeds from exercise of warrants and options	1,561	1,449	8
Total net cash provided by financing activities	1,586	12,043	9,721
EFFECT OF EXCHANGE RATE CHANGES ON CASH	5	6	(12)
INCREASE IN CASH AND CASH EQUIVALENTS	62	694	1,451
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,907	3,213	1,762
CASH AND CASH EQUIVALENTS AT END OF PERIOD	3,969	3,907	3,213
SUPPLEMENTARY DISCLOSURE ON CASH FLOWS -
Interest received	$ 833	$ 256	$ 115

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Aug. 31, 2017
Significant Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES: a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware. On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement, that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People's Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the "Product"). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%. The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and will end upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the "Royalty Term"). The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions. Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis. The initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016 and the fourth milestone payment of $4,000 was received in October 2016. In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015. The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company's shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement. Given the Company's continuing involvement through the expected product submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which the Company is entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees are earned. In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement. The following table summarizes the activities for deferred revenues for the years ended August 31, 2017 and 2016: August 31, 2017 2016 Deferred revenue at the beginning of period $ 14,766 $ - Amounts received 4,000 15,383 Amounts the Company was entitled to (24 ) 24 Revenue recognized (2,456 ) (641 ) Deferred revenue at the end of period 16,286 14,766 Less – current deferred revenue portion (2,449 ) (2,162 ) Non-current deferred revenue portion $ 13,837 $ 12,604 2) Development and liquidity risks The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities. b. Basis of presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation and to the expected product submission date for revenue recognition purposes. d. Functional currency The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate. e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation. f. Cash equivalents The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents. g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. As of August 31, 2017, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1). In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. As of August 31, 2017, the carrying amount of cash and cash equivalents, short-term deposits, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments. As of August 31, 2017, the carrying amount of long-term deposits approximates their fair values due to the stated interest rates which approximate market rates. The fair value of held to maturity bonds as presented in note 3 was based on a level 1 measurement. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value. There were no Level 3 items for the years ended August 31, 2017, 2016 and 2015. h. Marketable securities 1) Available-for-sale securities Available-for-sale equity securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of accumulated other comprehensive income (loss) in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses. Cost of the securities sold and amount reclassified out of accumulated other comprehensive income into financial income are determined by specific identification. 2) Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, management assesses whether there are any indicators that the value of the Company’s marketable securities may be impaired, which includes reviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and duration of the decline. In the Company’s evaluation, the Company considers its ability and intent to hold these investments for a reasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair value of the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To the extent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimated fair value in the security. i. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote. As of the date of issuing these financial statements, all amounts due from HTIT have been received, as described in note 1 above. j. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 10. Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities. Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses. k. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer and collection is reasonably assured. Given the Company's continuing involvement through the expected product submission (June 2023), revenue from the License Agreement is recognized over the periods from which the Company is entitled to the respective payments, and through the expected product submission date. l. Cost of revenues Cost of revenues consists of royalties related to the License Agreement with HTIT. The royalties are recognized when proceeds related to the License Agreement are received. m. Research and development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately. Grants received from the IIA and from the Bio-Jerusalem fund (“Bio-Jerusalem”) are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 6(j) and 6(k). n. Stock-based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options and restricted stock units (“RSUs”) with an exercise price using the Black Scholes pricing model, for stock options with market conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense is not reversed if the market conditions are not satisfied. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted to consultants and other non-employees is measured on a final basis at the end of the related service period using the Black Scholes pricing model and is recognized over the related service period using the straight-line method. The Company elects to account for forfeitures as they occur. o. Loss per common share Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and RSUs excluded from the calculation of diluted net loss was 1,827 ,719 p. Newly issued and recently adopted Accounting Pronouncements 1) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-09 (Topic 606) “Revenue from Contracts with Customers” that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle of this ASU is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for annual period ending on August 31, 2019 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 2) In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (ASU No. 2016-01) that will supersede most current guidance. Changes to the U.S. GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for annual period ending on August 31, 2019 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 3) In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASU 2016-02”), which supersedes the existing guidance for lease accounting, "Leases (Topic 840)". ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. 4) In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” ("ASU 2016-13"). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 5) In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flow - Classification of Certain Cash Receipts and Cash Payments (Topic 230)” ("ASU 2016-15"), which addresses a few specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this new pronouncement on its consolidated financial statements. 6) In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718) - Scope of Modification Accounting” ("ASU 2017-09"), which gives direction on which changes to the terms or conditions of share-based payment awards require an entity to apply modification accounting in ASC Topic 718. In general, entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements.

Short-Term Deposits

Short-Term Deposits	12 Months Ended
	Aug. 31, 2017
Short-Term Deposits/ Long-Term Deposits [Abstract]
SHORT-TERM DEPOSITS	NOTE 2 - SHORT-TERM DEPOSITS: Composition August 31, 2017 2016 Annual Amount Annual Amount Dollar deposits 1.84-5.95 % $ 13,293 0.85-2 % $ 24,254

Marketable Securities

Marketable Securities	12 Months Ended
	Aug. 31, 2017
Marketable Securities [Abstract]
MARKETABLE SECURITIES	NOTE 3 - MARKETABLE SECURITIES: a. Composition: The Company's marketable securities include investments in equity securities of D.N.A Biomedical Solutions Ltd (“D.N.A”) and in held to maturity bonds. Composition: August 31, 2017 2016 Short-term: D.N.A (see b below) $ 996 $ 701 Held to maturity bonds (see c below) 1,864 2,154 $ 2,860 $ 2,855 Long-term: Held to maturity bonds (see c below) $ 2,151 $ 530 b. D.N.A The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange. The fair value of those securities is measured at the quoted prices of the securities on the measurement date. During the years ended August 31, 2017, 2016 and 2015, the Company did not sell any of the D.N.A ordinary shares. As of August 31, 2017, the Company owns approximately 7.9% of D.N.A’s outstanding ordinary shares. The cost of the securities as of August 31, 2017 and 2016 and 2015 is $595. c. Held to maturity bonds The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2017, are as follows: August 31, 2017 Amortized Gross Estimated Short-term: Commercial bonds $ 1,823 $ (1 ) $ 1,822 Accrued interest 41 - 41 Long-term 2,151 - 2,151 $ 4,015 $ (1 ) $ 4,014 As of August 31, 2017, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $2,151 and the yield to maturity rates vary between 1.30% to 1.87%. The amortized cost and estimated fair value of held-to-maturity securities at August 31, 2016, are as follows: August 31, 2016 Amortized Gross Estimated fair value Short-term: Commercial bonds $ 2,118 $ - $ 2,118 Accrued interest 36 - 36 Long-term 530 1 531 $ 2,684 $ 1 $ 2,685 As of August 31, 2016, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $530, and the yield to maturity rates vary between 0.96% to 1.8%.

Long-Term Deposits

Long-Term Deposits	12 Months Ended
	Aug. 31, 2017
Short-Term Deposits/ Long-Term Deposits [Abstract]
LONG-TERM DEPOSITS	NOTE 4 - LONG-TERM DEPOSITS: Composition: August 31, 2017 2016 Bank deposits (see (1) below) $ 16,230 $ 11,038 Lease car deposits 1 4 Investment 1 1 $ 16,232 $ 11,043 (1) Represents U.S. dollar bank deposits which carry fixed annual interest rates between 2.06% to 2.56%, with maturities of more than one year from balance sheet date. The latest maturity date is during the year ending August 31, 2019.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Aug. 31, 2017
Accounts Payable and Accrued Expenses [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES: Composition: August 31, 2017 2016 Accounts payable $ 571 $ 365 Payroll and related accruals 97 66 Institutions 228 - Accrued liabilities 1,593 980 Other 227 - $ 2,716 $ 1,411

Commitments

Commitments	12 Months Ended
	Aug. 31, 2017
Commitments [Abstract]
COMMITMENTS	NOTE 6 - COMMITMENTS: a. In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd. (“Entera”) to D.N.A, retaining a 3% interest as of March 2011, which is accounted for as a cost method investment (amounting to $1). In consideration for the shares sold to D.N.A, the Company received, among other payments, 4,202,334 ordinary shares of D.N.A (see also note 3). As part of this agreement, the Subsidiary entered into a patent transfer agreement, according to which the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of August 31, 2017, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary. In addition, as part of a consulting agreement with a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011. b. On January 3, 2017, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 60 months commencing October 1, 2016. The annual lease payment will be New Israeli Shekel (“NIS”) 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of August 31, 2017, the future lease payments until the expiration of the lease agreement will be $143, based on the exchange rate as of August 31, 2017). As security for its obligation under this lease agreement, the Company provided a bank guarantee in an amount equal to three monthly lease payments. c. On March 3, 2016, the Subsidiary entered into an agreement with a vendor for process development and production of its capsules and on November 24, 2016, April 3, 2017 and July 10, 2017 into amendments to such agreement in an amount of up to Swiss Franc (“CHF”) 1,000,000 ($1,027), CHF 605,000 ($615) of which was recognized through August 31, 2017. d. On May 11, 2016, the Subsidiary entered into a Master Service Agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral GLP-1 analog capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $1,283 during the term of the engagement and based on achievement of certain milestones, of which $1,163 was recognized through August 31, 2017. e. On June 13, 2016, the Subsidiary entered into a four-year service agreement with a third party and on December 19, 2016, this agreement and all of the third party rights and obligations thereunder were assigned to another third party. This agreement is required by the License Agreement as described in note 1 and will support the Company's research and development. The Subsidiary is obligated to pay the third party a total amount of up to €2,360,000 ($2,726), of which €800,000 ($878) is a non-refundable fee to be paid within 12 months from the effective date, all of which was recognized in research and development through August 31, 2017. The remaining fee will be paid over the term of the engagement and will be based on achievement of certain milestones. f. On March 3, 2014, the Subsidiary entered into a Master Service Agreement with a vendor for the process development and production of one of its oral capsule ingredients in the amount of $311, $175 of which was recognized through August 31, 2017, and bonus payments of up to $600 that will be paid upon achieving certain milestones, as described in the agreement, none of which was recognized through August 31, 2017. On July 24, 2016, the Subsidiary entered into a General Technical Agreement with the same vendor, for the scale-up process development and production of the same capsule ingredients in the amount of $4,300 that will be paid over the term of the engagement and based on the achievement of certain development milestones, $3,327 of which were recognized in research and development through August 31, 2017. This agreement is part of the requirements of the License Agreement as described in note 1. g. On February 21, 2017, the Subsidiary entered into an agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral insulin capsule for type 2 and type 1 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total of up to $952 during the term of the engagement and based on achievement of certain milestones, of which $594 was recognized through August 31, 2017. h. On May 3, 2017, the Company entered into a consulting agreement with a third party advisor for a period of one year, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 10,000 shares of the Company’s common stock that will be issued in four equal quarterly installments commencing August 1, 2017. As of August 31, 2017, the Company had issued to such advisor 2,500 shares. The fair value of the shares at the grant date was $20. i. On June 5, 2017, the Subsidiary entered into a clinical research agreement with a vendor, for the conduct of its clamp clinical trial for an oral insulin capsule for type 1 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $958 during the term of the engagement and based on achievement of certain milestones, $160 of which was recognized through August 31, 2017. j. Grants from the Bio-Jerusalem Fund (“Bio-Jerusalem”) The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received (Israeli CPI linked) at the total amount of $65. The Company received no grants from Bio-Jerusalem since fiscal year 2013. Royalty expenses for the year ended August 31, 2017 of $47 are included in cost of revenues. As of August 31, 2017, the Subsidiary had realized revenues from its related project in the amount of $2,653. k. Grants from the IIA Under the terms of the Company’s funding from the IIA, royalties of 3.5% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR. At the time the grants were received, successful development of the related projects was not assured. The total amount that was received through August 31, 2017 was $2,194. Royalty expenses for the year ended August 31, 2017 of $140 are included in cost of revenues and will be paid over the term of the License Agreement in accordance with the revenue recognized from the related project. As of August 31, 2017, the Subsidiary had realized revenues from its project in the amount of $2,653. l. For the years ended August 31, 2017 and 2016, no grants from the IIA were recognized. For the year ended August 31, 2015, the research and development expenses are presented net of IIA grants in the total amount of $49.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Aug. 31, 2017
Stockholders' Equity [Abstract]
STOCKHOLDERS' EQUITY	NOTE 7 - STOCKHOLDERS’ EQUITY: The following are the significant capital stock transactions that took place during the years ended August 31, 2017, 2016 and 2015: a. On November 3, 2014, the Company entered into a Stock Purchase Agreement with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd., pursuant to which the Company issued to such investor an aggregate of 696,378 shares of common stock, at a price of $7.18 per share, which was equal to the closing price of the Company’s common stock on the Nasdaq Capital Market on October 31, 2014, for aggregate gross proceeds of approximately $5,000. The net proceeds to the Company from the offering were approximately $4,833, after deducting a finder's fee of $150 and other offering expenses of the Company. The offering closed on November 28, 2014. b. On April 2, 2015, the Company entered into an At The Market Issuance Sales Agreement and on April 5, 2017 into an amendment to such agreement (as amended, the “Sales Agreement”) with FBR Capital Markets & Co. (“FBR”) pursuant to which the Company may, from time to time and at its option, issue and sell shares of its common stock having an aggregate offering price of up to $25,000 through FBR as its sales agent, subject to certain terms and conditions. Any shares sold will be sold pursuant to the Company’s effective shelf registration statement on Form S-3 including a prospectus dated February 2, 2017, as supplemented by a prospectus supplement dated April 5, 2017. The Company will pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares sold through FBR. As of August 31, 2017, 2,970 shares were sold under the Sales Agreement and an additional 453,919 shares were subsequently sold during September and October 2017. c. On June 4, 2015, the Company entered into a letter of agreement (the “Engagement Letter”) with H.C. Wainwright & Co., LLC (“HCW”), pursuant to which HCW agreed to serve as exclusive agent, advisor or underwriter in any offering of the Company occurring between June 4, 2015 and July 4, 2015. On June 5, 2015, the Company entered into a Securities Purchase Agreement, pursuant to which the Company agreed to sell, in a registered direct offering (the “June 2015 Offering”): (1) an aggregate of 714,286 shares (the “Shares”) of the Company’s common stock at a price of $7.50 per Share to six investors (the “Purchasers”) and (2) at the option of each Purchaser (the “Overallotment Right”), additional shares of the Company’s common stock (the “Overallotment Shares”) up to the number equal to the number of the Shares purchased by such Purchaser and at a price of $10.00 per Overallotment Share. The closing of the sale of the Shares occurred on June 10, 2015. The Overallotment Right shall be exercisable beginning December 10, 2015, and shall remain exercisable until December 10, 2016. Pursuant to the Engagement Letter, HCW received, for its services in the June 2015 Offering, a fee equal to 7% of the gross proceeds raised in the June 2015 Offering and an expense allowance of 1% of the gross proceeds raised in the June 2015 Offering, and affiliates of HCW received warrants to purchase 28,571 shares of common stock of the Company, exercisable immediately and expires after a period of three years and with an exercise price of $10.00 per share. The net proceeds to the Company from the June 2015 Offering were approximately $4,880, after deducting HCW’s expenses and other offering expenses of the Company totaling $478. d. On December 28, 2015, the Company completed a private placement of 1,155,367 shares of the Company's common stock to HTIT. See also note 1. e. As of August 31, 2017, the Company had outstanding warrants exercisable for 166,642 shares of common stock at exercise prices ranging from $3.7656 to $10.00 per share and expiring at various dates between November 2, 2017 and June 10, 2018. The following table presents the warrant activity for the years ended August 31, 2017, 2016 and 2015: 2017 2016 2015 Warrants Weighted- Warrants Weighted- Warrants Weighted- Warrants outstanding as of September 1 615,338 $ 5.92 981,940 $ 5.29 953,369 $ 5.15 Issued - $ - - $ - 28,571 $ 10.00 Exercised (248,882 ) $ 4.99 (331,054 ) $ 4.04 - $ - Expired (199,814 ) $ 6.82 (35,548 ) $ 6.00 - $ - Warrants outstanding as of August 31 166,642 $ 6.46 615,338 $ 5.92 981,940 $ 5.29 Warrants exercisable as of August 31 166,642 $ 6.46 615,338 $ 5.92 981,496 $ 5.29

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Aug. 31, 2017
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 8 - STOCK-BASED COMPENSATION: As of August 31, 2017, the Company has one stock option plan, the Second Amended and Restated 2008 Stock Incentive Plan, under which, the Company had reserved a pool of 2,400,000 shares of the Company’s common stock which may be issued at the discretion of the Company’s Board of Directors from time to time. Under this Plan, each option is exercisable into one share of common stock of the Company. The options may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the options is 10 years. The following are the significant stock options transactions with employees, board members and non-employees made during the years ended August 31, 2017, 2016 and 2015: a. On November 13, 2014, the Company granted a total of 19,576 RSUs representing a right to receive shares of the Company’s common stock to the Company’s Chief Executive Officer (the "CEO"), and the Company’s Chief Scientific Officer (the "CSO"), both related parties. The RSUs vested in two equal installments, each of 9,788 shares, on November 30, 2014 and December 31, 2014. The total fair value of these RSUs on the date of grant was $135, using the quoted closing market share price of $6.90 on the Nasdaq on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2017, 9,788 RSUs were vested and outstanding and the remaining 9,788 were exercised. b. On November 13, 2014, the Company granted a total of 10,872 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors. The RSUs vested on January 1, 2015. The total fair value of these RSUs on the date of grant was $75, using the quoted closing market share price of $6.90 on the Nasdaq Capital Market on the date of grant. c. On February 23, 2015, the Company granted a total of 159,696 RSUs representing a right to receive shares of the Company’s common stock to the Company’s CEO and the CSO, both related parties. The RSUs vest in 23 installments consisting of one installment of 13,308 shares on February 28, 2015 and 22 equal monthly installments of 6,654 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $728, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2017, 79,848 RSUs were vested and outstanding and the remaining 79,848 were exercised. d. On February 23, 2015, the Company granted a total of 88,712 RSUs representing a right to receive shares of the Company’s common stock to four members of the Company's Board of Directors (22,178 RSUs to each director). The RSUs vested in two equal installments of 44,356 shares on each of December 31, 2015 and December 31, 2016. The total fair value of these RSUs on the date of grant was $405, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. On August 24, 2016 the Company determined, with respect to three of these members of the Company's Board of Directors, to accelerate the second installment of their RSUs, such that 22,179 RSUs were vested on August 29, 2016 and their remaining 11,088 RSUs were forfeited. e. On February 23, 2015, the Company granted a total of 63,216 RSUs to three employees of the Subsidiary. The RSUs vest in 23 installments, consisting of one installment of 5,268 shares on February 28, 2015 and 22 equal monthly installments of 2,634 shares each, commencing March 31, 2015. The total fair value of these RSUs on the date of grant was $288, using the quoted closing market share price of $4.56 on the Nasdaq Capital Market on the date of grant. f. On November 19, 2015, options to purchase an aggregate of 22,000 of the Company’s shares of common stock were granted to two consultants at an exercise price of $7.36 per share (equivalent to the traded market price on the date of grant) and expiration date of November 19, 2025. 10,000 of the options vested in one installment on December 1, 2015, and the remaining 12,000 options vest in twelve equal quarterly installments, commencing January 1, 2016. On August 3, 2016 the consulting agreement with one of these consultants, to whom 12,000 options were granted, was terminated. As a result, only 3,000 options were vested, and the remaining 9,000 unvested options were forfeited. In addition, the expiration date of the 3,000 vested options was updated to November 3, 2016 (3 months following the termination date of the agreement). g. On November 1, 2016, the Company granted a total of 70,000 RSUs representing a right to receive 70,000 shares of the Company’s common stock to an employee of the Subsidiary. The RSUs vest in 19 installments, consisting of one installment of 9,000 shares on November 1, 2016, 18 equal monthly installments of 1,500 shares each, commencing November 30, 2016 and 17,000 shares on each of April 30, 2017 and 2018. The total fair value of these RSUs on the date of grant was $463, using the quoted closing market share price of $6.62 on the Nasdaq Capital Market on the date of grant. h. On February 9, 2017, options to purchase an aggregate of 27,731 shares of the Company were granted to four members of the Company’s Board of Directors as follows: (a) 16,337 options at an exercise price of $1 per share (lower than the traded market price of $6.23 on the date of grant). The fair value of these options on the date of grant was $90, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years; (b) 11,394 options at an exercise price of $6.23 per share (equivalent to the traded market price on the date of grant). The fair value of these options on the date of grant was $45, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years. All the options vested immediately and expire on February 9, 2027. i. On March 20, 2017, options to purchase an aggregate of 37,152 of the Company’s shares of common stock were granted to a consultant at an exercise price of $6.00 per share (higher than the traded market price of $5.96 on the date of grant). The options expire on March 20, 2027. The options vest in 24 consecutive equal installments of 1,548 shares of common stock each, commencing March 31, 2017. The fair value of these options on the date of grant was $177. The fair value of these options as of August 31, 2017 was $261, using the Black Scholes option-pricing model and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 73.62%; risk-free interest rates of 2.12%; and expected term of 9.6 years. j. On June 30, 2017, the Company granted options to purchase shares of the Company and RSUs as follows: (1) To the CEO, options to purchase an aggregate of 147,000 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments of 49,000, on each of December 31, 2017, 2018 and 2019, subject to the Company share price reaching the target of $8.00 per share, $9.50 per share and $12.50 per share, respectively. These options expire on June 30, 2027. The fair value of the options at the date of grant was $585 using the Monte Carlo model, which utilizes multiple input variables to estimate the probability that market conditions will be achieved, and was based on the following assumptions: dividend yield of 0% for all years; expected volatility of 75.00%; risk-free interest rates of 2.34%; and expected term of 10 years. (2) To the CSO: (a) 75,000 RSUs representing a right to receive shares of the Company’s common stock which vested immediately, have an exercise price of $0.012 per share of common stock and expire on June 30, 2027. The total fair value of these RSUs on the date of grant was $582, using the quoted closing market share price of $7.77 on the Nasdaq Capital Market on the date of grant; The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2017, none of these RSUs were exercised. (b) options to purchase an aggregate of 69,999 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments of 23,333, on each of December 31, 2017, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $359, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years. (3) To four members of the Company’s Board of Directors, options to purchase an aggregate of 67,092 shares of the Company (16,773 options to each director), at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments, on each of December 31, 2017, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $344, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years. (4) To a member of the Company’s Board of Directors, options to purchase an aggregate of 56,773 shares of the Company at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in four annual installments, 15,591 of which shall vest on each of December 31, 2017, 2018 and 2019, and 10,000 of which shall vest on December 31, 2020. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $294, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.15%; risk-free interest rates of 2.14%; and expected term of 6.18 years. (5) To employees of the Subsidiary, options to purchase an aggregate of 38,901 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant). The options shall vest in three equal annual installments, on each of December 31, 2017, 2018 and 2019. These options expire on June 30, 2027. The fair value of all these options on the date of grant was $200, using the Black Scholes option-pricing model and was based on the following assumptions: stock price of $7.77; dividend yield of 0% for all years; expected volatility of 74.77%; risk-free interest rates of 1.89%; and expected term of 6 years. k. On July 19, 2017, options to purchase an aggregate of 20,001 shares of the Company were granted to an employee of the Subsidiary. The fair value of all these options on the date of grant was $113, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $8.57; dividend yield of 0% for all years; expected volatility of 74.65%; risk-free interest rates of 1.83%; and expected term of 6 years. l. Options to employees, directors and non-employees The fair value of each option grant is estimated on the date of grant using the Black Scholes option-pricing model or Monte Carlo model with the following assumptions: For options granted in the year ended August 31 2017 2016 Expected option life (years) 5.00-10.00 10.00 Expected stock price volatility (%) 74.15-77.29 80.46 Risk free interest rate (%) 1.83-2.47 2.24 Expected dividend yield (%) 0.0 0.0 No options were granted in fiscal year 2015. A summary of the status of the stock options granted to employees and directors as of August 31, 2017, 2016 and 2015, and changes during the years ended on those dates, is presented below: Year ended August 31, 2017 2016 2015 Number of options Weighted Number Weighted Number Weighted $ $ $ Options outstanding at beginning of year 904,234 6.75 904,234 6.75 908,901 6.75 Changes during the year: Granted 427,497 7.51 - - - - Forfeited - - - - (3,297 ) 6.00 Expired (59,282 ) 10.27 Exercised 63,900 5 - - (1,370 ) 6.00 Options outstanding at end of year 1,208,549 6.94 904,234 6.75 904,234 6.75 Options exercisable at end of year 808,783 904,234 883,234 Weighted average fair value of options granted during the year $ 4.75 $ - $ - Costs incurred in respect of stock options granted to employees and directors, for the years ended August 31, 2017, 2016 and 2015 were $451, $14 and $278, respectively. The total intrinsic value of employees' options exercised during the year ended August 31, 2017 was $85. None of the options were exercised by employees during the year ended August 31, 2016. The options exercised during the year ended August 31, 2015, were at a price equal to the market price at the exercise date. The following table presents summary information concerning the options granted to employees and directors outstanding as of August 31, 2017: Range of Number Weighted Weighted Aggregate $ Years $ $ 1.00 to 6.00 442,671 3.92 4.74 1,730,803 6.48 to 7.88 635,959 7.09 7.47 751,863 8.57 to 12.45 129,919 7.12 11.85 1,600 1,208,549 5.93 6.94 2,484,266 808,783 of options granted to employees and directors that were outstanding as of August 31, 2017, were also exercisable as of August 31, 2017. As of August 31, 2017, there were $1,579 of unrecognized compensation costs related to non-vested options previously granted to employees and directors. The unrecognized compensation costs are expected to be recognized over a weighted average period of 2.5 years. A summary of the status of the stock options granted to non-employees outstanding as of August 31, 2017, 2016 and 2015, and changes during the years ended on this date, is presented below: Year ended August 31, 2017 2016 2015 Number Weighted Number Weighted Number Weighted $ $ $ Options outstanding at beginning of year 29,668 8.35 40,286 7.29 62,221 7.13 Changes during the year: Granted 37,152 6.00 22,000 7.36 Exercised - - (18,718 ) 6.00 - - Forfeited - - (9,000 ) 7.36 Expired (11,334 ) 8.65 (4,900 ) 6.00 (21,935 ) 6.82 Options outstanding at end of year 55,486 6.71 29,668 8.35 40,286 7.29 Options exercisable at end of year 27,622 29,668 36,119 The Company recorded stock-based compensation of $59, $102 and $3 during the years ended August 31, 2017, 2016 and 2015, respectively, related to non-employees' awards. The total intrinsic value of non-employees' options exercised during the year ended August 31, 2016, was $37. None of the options were exercised by non-employees during the years ended August 31, 2017 and 2015. The following table presents summary information concerning the options granted to non-employees outstanding as of August 31, 2017: Range of Number Weighted Weighted Aggregate $ Years $ $ 6.00 37,152 9.56 6.00 98,453 7.36 10,000 8.22 7.36 12,900 9.12 8,334 1.36 9.12 - 55,486 8.09 6.71 111,353 27,622 options granted to non-employees and directors that were outstanding as of August 31, 2017, were also exercisable as of August 31, 2017. As of August 31, 2017, there were $196 of unrecognized compensation costs related to non-vested non-employee options. The unrecognized compensation costs are expected to be recognized over a weighted average period of 1.5 years. m. Restricted stock units The following table summarizes the activities for unvested RSUs granted to employees and directors for the years ended August 31, 2017, 2016 and 2015: Year ended August 31, 2017 2016 2015 Number of RSUs Unvested at the beginning of period 201,669 313,216 - Granted 178,120 1,000 346,704 Vested and issued (159,353 ) (101,459 ) (33,488 ) Forfeited (22,160 ) (11,088 ) - Outstanding at the end of the period 198,276 201, 669 313,216 Vested and unissued (see notes 8a, 8c and 8j(2)) 164,636 152,656 72,808 The Company recorded compensation costs related to RSUs of $1,064, $518 and $1,066, during the years ended August 31, 2017, 2016 and 2015, respectively, related to RSU awards. As of August 31, 2017, there were $88 unrecognized compensation costs related to RSUs, to be recorded over the next 12 months.

Financial Income and Expenses

Financial Income and Expenses	12 Months Ended
	Aug. 31, 2017
Financial Income and Expenses [Abstract]
FINANCIAL INCOME AND EXPENSES	NOTE 9 - FINANCIAL INCOME AND EXPENSES a. Financial income Year ended August 31, 2017 2016 2015 Income from interest on deposits $ 657 $ 378 $ 160 Exchange rate differences 7 - - Income from interest on corporate bonds 128 96 8 $ 792 $ 474 $ 168 b. Financial expenses Year ended August 31, 2017 2016 2015 Exchange rate differences $ 17 $ 17 $ 3 Bank commissions 6 11 9 Other 78 65 6 $ 101 $ 93 $ 18

Taxes on Income

Taxes on Income	12 Months Ended
	Aug. 31, 2017
Taxes on Income [Abstract]
TAXES ON INCOME	NOTE 10 - TAXES ON INCOME: Taxes on income included in the consolidated statements of operations represent current taxes due to taxable income of the Company and its Subsidiary. a. Corporate taxation in the U.S. The applicable corporate tax rate for the Company is 35%. As of August 31, 2017, the Company has an accumulated tax loss carryforward of approximately $10,060 (as of August 31, 2016, approximately $8,945). Under U.S. tax laws, subject to certain limitations, carryforward tax losses expire 20 years after the year in which incurred. In the case of the Company, subject to potential limitations in accordance with the relevant law, the net loss carryforward will expire in the years 2025 through 2037. b. Corporate taxation in Israel: The Subsidiary is taxed in accordance with Israeli tax laws. The corporate tax rates applicable to 2017, 2016 and 2015 are 24%, 25% and 26.5%, respectively. As of August 31, 2017, the Subsidiary has an accumulated tax loss carryforward of approximately $26,881 (as of August 31, 2016, approximately $18,580). Under the Israeli tax laws, carryforward tax losses have no expiration date. Deferred income taxes: August 31, 2017 2016 2015 In respect of: Net operating loss carryforward $ 9,253 $ 9,219 $ 5,750 Research and development expenses 2,046 - 906 Less - valuation allowance (11,299 ) (9,219 ) (6,656 ) Net deferred tax assets $ - $ - $ - Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carryforwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a full valuation allowance. c. Loss before taxes on income and income taxes included in the income statements of operations: Year ended August 31, 2017 2016 2015 Loss before taxes on income: U.S. $ 1,115 $ 959 $ 1,226 Outside U.S. 8,965 8,670 6,007 $ 10,080 $ 9,629 $ 7,233 Taxes on income (tax benefit): Current: U.S. - (15 ) - Outside U.S. 400 1,350 (1 ) $ 400 $ 1,335 $ (1 ) Taxes on income of $400 is derived from withholding tax deducted from HTIT milestones payments, which were received during the year ended August 31, 2017, according to the License Agreement. As of August 31, 2017, the Company did not expect to reach taxable income in the 5 years following the balance sheet date, and therefore recognized this amount as taxes on income. d. Reconciliation of the statutory tax benefit to effective tax expense Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to companies in the United States, and the actual tax expense: Year ended August 31, 2017 2016 2015 Loss before income taxes as reported in the consolidated statement of comprehensive loss $ (10,080 ) $ (9,629 ) $ (7,233 ) Statutory tax benefit (3,528 ) (3,370 ) (2,531 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax 2,080 2,563 1,599 Disallowable deductions 327 167 422 Influence of different tax rates and changes in tax rates applicable to the Subsidiary 1,121 640 510 Withholding tax, see note 10c above 400 1,350 - Uncertain tax position - (15 ) (1 ) Taxes on income (tax benefit) for the reported year $ 400 $ 1,335 $ (1 ) e. Uncertainty in Income Taxes Accounting Standards Codification No.740 “Income Taxes” requires significant judgment in determining what constitutes an individual tax position as well as assessing the outcome of each tax position. Changes in judgment as to recognition or measurement of tax positions can materially affect the estimate of the effective tax rate and consequently, affect the operating results of the Company. The Company recognizes interest and penalties related to its tax contingencies as income tax expense. The following table summarizes the activity of the Company unrecognized tax benefits: Year ended August 31, 2017 2016 2015 Balance at Beginning of Year $ 11 $ 26 27 Decrease in uncertain tax positions for the current year - (15 ) (1 ) Balance at End of Year $ 11 $ 11 $ 26 The CoThe Company does not expect unrecognized tax expenses to change significantly over the next 12 months. The Company is subject to U.S. Federal income tax examinations for the tax years of 2013 through 2017. The Subsidiary is subject to Israeli income tax examinations for the tax years of 2013 through 2017. f. Valuation Allowance Rollforward Year ended August 31, Balance at beginning of period Additions Balance at end of period Allowance in respect of carryforward tax losses: Year ended August 31, 2017 $ 9,219 $ 2,080 $ 11,299 Year ended August 31, 2016 $ 6,656 2,563 9,219 Year ended August 31, 2015 $ 5,578 $ 1,078 $ 6,656

Related Parties - Transactions

Related Parties - Transactions	12 Months Ended
	Aug. 31, 2017
Related Parties - Transactions [Abstract]
RELATED PARTIES - TRANSACTIONS	NOTE 11 - RELATED PARTIES - TRANSACTIONS: a. During each of the fiscal years of 2017, 2016 and 2015 the Company paid to directors $100, $92 and $47, respectively, as directors' fees. b. On July 1, 2008, the Subsidiary entered into two consulting agreements with KNRY Ltd. (“KNRY”), an Israeli company owned by the CEO, whereby the CEO and the CSO, through KNRY, provide services to the Company (the “Consulting Agreements”). The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($35) and NIS 80,454 ($22), respectively. c. Balances with related parties: August 31, 2017 2016 Accounts payable and accrued expenses - KNRY $ - $ 48 d. Expenses to related parties: Year ended August 31, 2017 2016 2015 KNRY $ 868 $ 839 $ 586

Significant Accounting Polici18

Significant Accounting Policies (Policies)	12 Months Ended
	Aug. 31, 2017
Significant Accounting Policies [Abstract]
General	a. General 1) Incorporation and operations Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd. (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes. On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development. On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware. On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015, the parties entered into an Amended and Restated Technology License Agreement, that was further amended by the parties on June 3, 2016 and July 24, 2016 (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the People's Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801 (the "Product"). Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 was payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be paid upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%. The royalty payment obligation shall apply during the period of time beginning upon the first commercial sale of the Product in the Territory, and will end upon the later of (i) the expiration of the last-to-expire licensed patents in the Territory; and (ii) 15 years after the first commercial sale of the Product in the Territory (the "Royalty Term"). The License Agreement shall remain in effect until the expiration of the Royalty Term. The License Agreement contains customary termination provisions. Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as advisory services to HTIT on an ongoing basis. The initial payment of $3,000 was received in January 2016. Following the achievement of certain milestones, the second and third payments of $6,500 and $4,000, respectively, were received in July 2016 and the fourth milestone payment of $4,000 was received in October 2016. In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement with HTIT (the “SPA”). According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT for $12,000. The transaction closed on December 28, 2015. The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of common stock (less issuance expenses of $23), based on the quoted price of the Company's shares on the closing date of the SPA on December 28, 2015, and $38,883 was allocated to the License Agreement. Given the Company's continuing involvement through the expected product submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which the Company is entitled to the respective payment, and the expected product submission date using a time-based model approach over the periods that the fees are earned. In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement. The following table summarizes the activities for deferred revenues for the years ended August 31, 2017 and 2016: August 31, 2017 2016 Deferred revenue at the beginning of period $ 14,766 $ - Amounts received 4,000 15,383 Amounts the Company was entitled to (24 ) 24 Revenue recognized (2,456 ) (641 ) Deferred revenue at the end of period 16,286 14,766 Less – current deferred revenue portion (2,449 ) (2,162 ) Non-current deferred revenue portion $ 13,837 $ 12,604 2) Development and liquidity risks The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable. Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, obtaining foreign regulatory approvals to sell its products internationally, or entering into licensing agreements with third parties. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.
Basis of presentation	b. Basis of presentation The consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”).
Use of estimates in the preparation of financial statements	c. Use of estimates in the preparation of financial statements The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the financial statements date and the reported expenses during the reporting periods. Actual results could differ from those estimates. As applicable to these consolidated financial statements, the most significant estimates and assumptions relate to stock-based compensation and to the expected product submission date for revenue recognition purposes.
Functional currency	d. Functional currency The currency of the primary economic environment in which the operations of the Company and its Subsidiary are conducted is the U.S. dollar (“$” or “dollar”). Therefore, the functional currency of the Company and its Subsidiary is the dollar. Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in foreign currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For foreign transactions and other items reflected in the statements of operations, the following exchange rates are used: (1) for transactions - exchange rates at transaction dates or average rates and (2) for other items (derived from non-monetary balance sheet items such as depreciation) - historical exchange rates. The resulting transaction gains or losses are carried to financial income or expenses, as appropriate.
Principles of consolidation	e. Principles of consolidation The consolidated financial statements include the accounts of the Company and its Subsidiary. All inter-company transactions and balances have been eliminated in consolidation.
Cash equivalents	f. Cash equivalents The Company considers all short-term, highly liquid investments, which include short-term deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash, to be cash equivalents.
Fair value measurement	g. Fair value measurement: The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. As of August 31, 2017, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1). In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible. As of August 31, 2017, the carrying amount of cash and cash equivalents, short-term deposits, other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments. As of August 31, 2017, the carrying amount of long-term deposits approximates their fair values due to the stated interest rates which approximate market rates. The fair value of held to maturity bonds as presented in note 3 was based on a level 1 measurement. The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value. There were no Level 3 items for the years ended August 31, 2017, 2016 and 2015.
Marketable securities	h. Marketable securities 1) Available-for-sale securities Available-for-sale equity securities are reported at fair value, with unrealized gains and losses, net of related tax recorded as a separate component of accumulated other comprehensive income (loss) in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities. The Company considers available evidence in evaluating potential impairments of its investments, including the duration and extent to which fair value is less than cost, and the Company’s ability and intent to hold the investment. Realized gains and losses on sales of the securities are included in the consolidated statement of operations as financial income or expenses. Cost of the securities sold and amount reclassified out of accumulated other comprehensive income into financial income are determined by specific identification. 2) Held to maturity securities All debt securities are classified as held-to-maturity because the Company has the positive intent and ability to hold the securities to maturity. Held-to-maturity securities are stated at amortized cost, adjusted for amortization of premiums and accretion of discounts to maturity. On a continuous basis, management assesses whether there are any indicators that the value of the Company’s marketable securities may be impaired, which includes reviewing the underlying cause of any decline in value and the estimated recovery period, as well as the severity and duration of the decline. In the Company’s evaluation, the Company considers its ability and intent to hold these investments for a reasonable period of time sufficient for the Company to recover its cost basis. A marketable security is impaired if the fair value of the security is less than the carrying value of the security and such difference is deemed to be other-than temporary. To the extent impairment has occurred, the loss shall be measured as the excess of the carrying amount of the security over the estimated fair value in the security.
Concentration of credit risks	i. Concentration of credit risks Financial instruments that subject the Company to credit risk consist primarily of cash and cash equivalents, short and long-term deposits and marketable securities which are deposited in major financial institutions. The Company is of the opinion that the credit risk in respect of these balances is remote. As of the date of issuing these financial statements, all amounts due from HTIT have been received, as described in note 1 above.
Income taxes	j. Income taxes 1. Deferred taxes Deferred taxes are determined utilizing the asset and liability method based on the estimated future tax effects of differences between the financial accounting and tax bases of assets and liabilities under the applicable tax laws. Deferred tax balances are computed using the tax rates expected to be in effect when those differences reverse. A valuation allowance in respect of deferred tax assets is provided if, based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. The Company has provided a full valuation allowance with respect to its deferred tax assets. See note 10. Regarding the Subsidiary, the recognition is prohibited for deferred tax liabilities or assets that arise from differences between the financial reporting and tax bases of assets and liabilities that are measured from the local currency into dollars using historical exchange rates, and that result from changes in exchange rates or indexing for tax purposes. Consequently, the abovementioned differences were not reflected in the computation of deferred tax assets and liabilities. Taxes that would apply in the event of disposal of investments in the Subsidiary have not been taken into account in computing deferred taxes, as it is the Company’s intention to hold this investment, not to realize it. 2. Uncertainty in income tax The Company follows a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement. Such liabilities are classified as long-term, unless the liability is expected to be resolved within twelve months from the balance sheet date. The Company’s policy is to include interest and penalties related to unrecognized tax benefits within income tax expenses.
Revenue recognition	k. Revenue recognition Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer and collection is reasonably assured. Given the Company's continuing involvement through the expected product submission (June 2023), revenue from the License Agreement is recognized over the periods from which the Company is entitled to the respective payments, and through the expected product submission date.
Cost of revenues	l. Cost of revenues Cost of revenues consists of royalties related to the License Agreement with HTIT. The royalties are recognized when proceeds related to the License Agreement are received.
Research and development, net	m. Research and development, net Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, employee benefits, the cost of supplies, the cost of services provided by outside contractors, including services related to the Company’s clinical trials, clinical trial expenses and the full cost of manufacturing drug for use in research and preclinical development. All costs associated with research and development are expensed as incurred. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as Contract Research Organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, clinical trial costs are expensed immediately. Grants received from the IIA and from the Bio-Jerusalem fund (“Bio-Jerusalem”) are recognized as grant income when the grants become receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grants are deducted from the related research and development expenses as the costs are incurred and are presented in R&D expenses, net. See also notes 6(j) and 6(k).
Stock-based compensation	n. Stock-based compensation Equity awards granted to employees are accounted for using the grant date fair value method. The grant date fair value is determined as follows: for stock options and restricted stock units (“RSUs”) with an exercise price using the Black Scholes pricing model, for stock options with market conditions using a Monte Carlo model and for RSUs with service conditions based on the grant date share price. The fair value of share based payment awards is recognized as an expense over the requisite service period. The expected term is the length of time until the expected dates of exercising the award and is estimated using the simplified method due to insufficient specific historical information of employees' exercise behavior, unless the award includes a market condition, in which case the contractual term is used. The volatility is based on a historical volatility, by statistical analysis of the weekly share price for past periods. The Company elected to recognize compensation cost for awards granted to employees that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. For awards with only market conditions, compensation expense is not reversed if the market conditions are not satisfied. When stock options are granted as consideration for services provided by consultants and other non-employees, the transaction is accounted for based on the fair value of the consideration received or the fair value of the stock options issued, whichever is more reliably measurable. The fair value of the options granted to consultants and other non-employees is measured on a final basis at the end of the related service period using the Black Scholes pricing model and is recognized over the related service period using the straight-line method. The Company elects to account for forfeitures as they occur.
Loss per common share	o. Loss per common share Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding for each period. Outstanding stock options, warrants and RSUs have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and RSUs excluded from the calculation of diluted net loss was 1,827 ,719
Newly issued and recently adopted Accounting Pronouncements	p. Newly issued and recently adopted Accounting Pronouncements 1) In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") No. 2014-09 (Topic 606) “Revenue from Contracts with Customers” that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle of this ASU is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for annual period ending on August 31, 2019 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 2) In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (ASU No. 2016-01) that will supersede most current guidance. Changes to the U.S. GAAP model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The guidance is effective in annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. The Company will implement the guidance for annual period ending on August 31, 2019 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 3) In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASU 2016-02”), which supersedes the existing guidance for lease accounting, "Leases (Topic 840)". ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements. 4) In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” ("ASU 2016-13"). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the guidance on its consolidated financial statements. 5) In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flow - Classification of Certain Cash Receipts and Cash Payments (Topic 230)” ("ASU 2016-15"), which addresses a few specific cash flow issues with the objective of reducing the existing diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company is currently evaluating the impact of this new pronouncement on its consolidated financial statements. 6) In May 2017, the FASB issued ASU 2017-09, “Compensation - Stock Compensation (Topic 718) - Scope of Modification Accounting” ("ASU 2017-09"), which gives direction on which changes to the terms or conditions of share-based payment awards require an entity to apply modification accounting in ASC Topic 718. In general, entities will apply the modification accounting guidance if the value, vesting conditions or classification of the award changes. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption is permitted, including adoption in an interim period. The Company does not expect the implementation of this new pronouncement to have a material impact on its consolidated financial statements.

Significant Accounting Polici19

Significant Accounting Policies (Tables)	12 Months Ended
	Aug. 31, 2017
Significant Accounting Policies [Abstract]
Schedule of activities for deferred revenues	August 31, 2017 2016 Deferred revenue at the beginning of period $ 14,766 $ - Amounts received 4,000 15,383 Amounts the Company was entitled to (24 ) 24 Revenue recognized (2,456 ) (641 ) Deferred revenue at the end of period 16,286 14,766 Less – current deferred revenue portion (2,449 ) (2,162 ) Non-current deferred revenue portion $ 13,837 $ 12,604

Short-Term Deposits (Tables)

Short-Term Deposits (Tables)	12 Months Ended
	Aug. 31, 2017
Short-Term Deposits/ Long-Term Deposits [Abstract]
Schedule of short-term debt	August 31, 2017 2016 Annual Amount Annual Amount Dollar deposits 1.84-5.95 % $ 13,293 0.85-2 % $ 24,254

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Aug. 31, 2017
Marketable Securities [Abstract]
Schedule of marketable securities include investments in equity securities	August 31, 2017 2016 Short-term: D.N.A (see b below) $ 996 $ 701 Held to maturity bonds (see c below) 1,864 2,154 $ 2,860 $ 2,855 Long-term: Held to maturity bonds (see c below) $ 2,151 $ 530
Schedule of amortized cost and estimated fair value of held-to-maturity securities	August 31, 2017 Amortized Gross Estimated Short-term: Commercial bonds $ 1,823 $ (1 ) $ 1,822 Accrued interest 41 - 41 Long-term 2,151 - 2,151 $ 4,015 $ (1 ) $ 4,014 August 31, 2016 Amortized Gross Estimated fair value Short-term: Commercial bonds $ 2,118 $ - $ 2,118 Accrued interest 36 - 36 Long-term 530 1 531 $ 2,684 $ 1 $ 2,685

Long-Term Deposits (Tables)

Long-Term Deposits (Tables)	12 Months Ended
	Aug. 31, 2017
Short-Term Deposits/ Long-Term Deposits [Abstract]
Schedule of long-term deposits	August 31, 2017 2016 Bank deposits (see (1) below) $ 16,230 $ 11,038 Lease car deposits 1 4 Investment 1 1 $ 16,232 $ 11,043 (1) Represents U.S. dollar bank deposits which carry fixed annual interest rates between 2.06% to 2.56%, with maturities of more than one year from balance sheet date. The latest maturity date is during the year ending August 31, 2019.

Accounts Payable and Accrued 23

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Aug. 31, 2017
Accounts Payable and Accrued Expenses [Abstract]
Schedule of accounts payable and accrued expenses	August 31, 2017 2016 Accounts payable $ 571 $ 365 Payroll and related accruals 97 66 Institutions 228 - Accrued liabilities 1,593 980 Other 227 - $ 2,716 $ 1,411

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Aug. 31, 2017
Stockholders' Equity [Abstract]
Schedule of warrant activity	2017 2016 2015 Warrants Weighted- Warrants Weighted- Warrants Weighted- Warrants outstanding as of September 1 615,338 $ 5.92 981,940 $ 5.29 953,369 $ 5.15 Issued - $ - - $ - 28,571 $ 10.00 Exercised (248,882 ) $ 4.99 (331,054 ) $ 4.04 - $ - Expired (199,814 ) $ 6.82 (35,548 ) $ 6.00 - $ - Warrants outstanding as of August 31 166,642 $ 6.46 615,338 $ 5.92 981,940 $ 5.29 Warrants exercisable as of August 31 166,642 $ 6.46 615,338 $ 5.92 981,496 $ 5.29

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Aug. 31, 2017
Stock-Based Compensation [Abstract]
Schedule of fair value of option grant using the Black Scholes option-pricing model	For options granted in the year ended August 31 2017 2016 Expected option life (years) 5.00-10.00 10.00 Expected stock price volatility (%) 74.15-77.29 80.46 Risk free interest rate (%) 1.83-2.47 2.24 Expected dividend yield (%) 0.0 0.0
Schedule of stock options granted to employees and directors	Year ended August 31, 2017 2016 2015 Number of options Weighted Number Weighted Number Weighted $ $ $ Options outstanding at beginning of year 904,234 6.75 904,234 6.75 908,901 6.75 Changes during the year: Granted 427,497 7.51 - - - - Forfeited - - - - (3,297 ) 6.00 Expired (59,282 ) 10.27 Exercised 63,900 5 - - (1,370 ) 6.00 Options outstanding at end of year 1,208,549 6.94 904,234 6.75 904,234 6.75 Options exercisable at end of year 808,783 904,234 883,234 Weighted average fair value of options granted during the year $ 4.75 $ - $ -
Schedule of options granted to employees and directors outstanding and exercisable	Range of Number Weighted Weighted Aggregate $ Years $ $ 1.00 to 6.00 442,671 3.92 4.74 1,730,803 6.48 to 7.88 635,959 7.09 7.47 751,863 8.57 to 12.45 129,919 7.12 11.85 1,600 1,208,549 5.93 6.94 2,484,266
Schedule of stock options granted to non-employees outstanding	Year ended August 31, 2017 2016 2015 Number Weighted Number Weighted Number Weighted $ $ $ Options outstanding at beginning of year 29,668 8.35 40,286 7.29 62,221 7.13 Changes during the year: Granted 37,152 6.00 22,000 7.36 Exercised - - (18,718 ) 6.00 - - Forfeited - - (9,000 ) 7.36 Expired (11,334 ) 8.65 (4,900 ) 6.00 (21,935 ) 6.82 Options outstanding at end of year 55,486 6.71 29,668 8.35 40,286 7.29 Options exercisable at end of year 27,622 29,668 36,119
Schedule of concerning the options granted to non-employees outstanding and exercisable	Range of Number Weighted Weighted Aggregate $ Years $ $ 6.00 37,152 9.56 6.00 98,453 7.36 10,000 8.22 7.36 12,900 9.12 8,334 1.36 9.12 - 55,486 8.09 6.71 111,353
Schedule of activities for unvested RSUs granted to employees and directors	Year ended August 31, 2017 2016 2015 Number of RSUs Unvested at the beginning of period 201,669 313,216 - Granted 178,120 1,000 346,704 Vested and issued (159,353 ) (101,459 ) (33,488 ) Forfeited (22,160 ) (11,088 ) - Outstanding at the end of the period 198,276 201, 669 313,216 Vested and unissued (see notes 8a, 8c and 8j(2)) 164,636 152,656 72,808

Financial Income and Expenses (

Financial Income and Expenses (Tables)	12 Months Ended
	Aug. 31, 2017
Financial Income and Expenses [Abstract]
Schedule of financial income	Year ended August 31, 2017 2016 2015 Income from interest on deposits $ 657 $ 378 $ 160 Exchange rate differences 7 - - Income from interest on corporate bonds 128 96 8 $ 792 $ 474 $ 168
Schedule of financial expenses	Year ended August 31, 2017 2016 2015 Exchange rate differences $ 17 $ 17 $ 3 Bank commissions 6 11 9 Other 78 65 6 $ 101 $ 93 $ 18

Taxes on Income (Tables)

Taxes on Income (Tables)	12 Months Ended
	Aug. 31, 2017
Taxes on Income [Abstract]
Schedule of deferred income taxes	August 31, 2017 2016 2015 In respect of: Net operating loss carryforward $ 9,253 $ 9,219 $ 5,750 Research and development expenses 2,046 - 906 Less - valuation allowance (11,299 ) (9,219 ) (6,656 ) Net deferred tax assets $ - $ - $ -
Schedule of income taxes included in the income statements	Year ended August 31, 2017 2016 2015 Loss before taxes on income: U.S. $ 1,115 $ 959 $ 1,226 Outside U.S. 8,965 8,670 6,007 $ 10,080 $ 9,629 $ 7,233 Taxes on income (tax benefit): Current: U.S. - (15 ) - Outside U.S. 400 1,350 (1 ) $ 400 $ 1,335 $ (1 )
Schedule of reconciliation of income taxes	Year ended August 31, 2017 2016 2015 Loss before income taxes as reported in the consolidated statement of comprehensive loss $ (10,080 ) $ (9,629 ) $ (7,233 ) Statutory tax benefit (3,528 ) (3,370 ) (2,531 ) Increase (decrease) in income taxes resulting from: Change in the balance of the valuation allowance for deferred tax 2,080 2,563 1,599 Disallowable deductions 327 167 422 Influence of different tax rates and changes in tax rates applicable to the Subsidiary 1,121 640 510 Withholding tax, see note 10c above 400 1,350 - Uncertain tax position - (15 ) (1 ) Taxes on income (tax benefit) for the reported year $ 400 $ 1,335 $ (1 )
Schedule of unrecognized tax benefits activity	Year ended August 31, 2017 2016 2015 Balance at Beginning of Year $ 11 $ 26 27 Decrease in uncertain tax positions for the current year - (15 ) (1 ) Balance at End of Year $ 11 $ 11 $ 26
Schedule of valuation allowance rollforward	Year ended August 31, Balance at beginning of period Additions Balance at end of period Allowance in respect of carryforward tax losses: Year ended August 31, 2017 $ 9,219 $ 2,080 $ 11,299 Year ended August 31, 2016 $ 6,656 2,563 9,219 Year ended August 31, 2015 $ 5,578 $ 1,078 $ 6,656

Related Parties - Transactions

Related Parties - Transactions (Tables)	12 Months Ended
	Aug. 31, 2017
Related Parties - Transactions [Abstract]
Schedule of balances with related parties	August 31, 2017 2016 Accounts payable and accrued expenses - KNRY $ - $ 48
Schedule of expenses to related parties	Year ended August 31, 2017 2016 2015 KNRY $ 868 $ 839 $ 586

Significant Accounting Polici29

Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Significant Accounting Policies [Abstract]
Deferred revenue at the beginning of period	$ 14,766
Amounts received	4,000	15,383
Amounts the Company was entitled to	(24)	24
Revenue recognized	(2,456)	(641)
Deferred revenue at the end of period	16,286	14,766
Less - current deferred revenue portion	2,449	2,162
Non-current deferred revenue portion	$ 13,837	$ 12,604

Significant Accounting Polici30

Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	Oct. 31, 2016	Jul. 31, 2016	Jan. 31, 2016	Dec. 28, 2015	Nov. 30, 2015	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015	Jul. 31, 2015
Significant Accounting Policies (Textual)
Milestone payment received			$ 3,000
Number of common stock issued ,value				$ 49,500		$ 25	$ 10,594
Recognize revenue						$ 2,456	$ 641
Securities excluded from the calculation of diluted net loss						1,827,719	2,676,573	2,249,164
Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value				10,617
Issuance expenses				23
License Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued ,value				$ 38,883
Second Milestone [Member]
Significant Accounting Policies (Textual)
Milestone payment received		$ 6,500
Second Milestone [Member] | License Agreement [Member]
Significant Accounting Policies (Textual)
Aggregate license costs						$ 19,383
Recognize revenue						3,097
Deferred costs						$ 16,286
Third Milestone [Member]
Significant Accounting Policies (Textual)
Milestone payment received		$ 4,000
Forth milestone [Member]
Significant Accounting Policies (Textual)
Milestone payment received	$ 4,000
HTIT [Member]
Significant Accounting Policies (Textual)
Percentages of royalties on net sales						10.00%
Aggregate license costs						$ 37,500
License costs payable						3,000
Amount paid subject to the Company entering into certain agreements						8,000
Payable upon achievement of certain milestones and conditions						$ 26,500
Royalty commitment description						In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the final expiration of the Company's patents covering the technology in the Territory in 2033, the Royalties rate may be reduced, under certain circumstances, to 5%.
Royalty term						15 years
Non-refundable amount									$ 500
HTIT [Member] | Stock Purchase Agreement [Member]
Significant Accounting Policies (Textual)
Number of common stock issued					1,155,367
Number of common stock issued ,value					$ 12,000

Short-Term Deposits (Details)

Short-Term Deposits (Details) - Dollar Deposits [Member] - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Short-term Debt [Line Items]
Short-term deposits	$ 13,293	$ 24,254
Minimum [Member]
Short-term Debt [Line Items]
Annual interest rate	1.84%	0.85%
Maximum [Member]
Short-term Debt [Line Items]
Annual interest rate	5.95%	2.00%

Marketable Securities (Details)

Marketable Securities (Details) - USD ($) $ in Thousands	Aug. 31, 2017	Aug. 31, 2016
Short-term:
D.N.A (see b below)	$ 996	$ 701
Held to maturity bonds (see c below)	1,864	2,154
Marketable securities	2,860	2,855
Long-term:
Held to maturity bonds (see c below)	$ 2,151	$ 530

Marketable Securities (Details

Marketable Securities (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Marketable Securities, Current [Abstract]
Maturity securities Amortized cost	$ 4,015	$ 2,684
Maturity securities Gross unrealized gains (losses)	(1)	1
Maturity securities Estimated fair value	4,014	2,685
Long-term [Member]
Marketable Securities, Current [Abstract]
Maturity securities Amortized cost	2,151	530
Maturity securities Gross unrealized gains (losses)		1
Maturity securities Estimated fair value	2,151	531
Accrued interest [Member] | Short-term [Member]
Marketable Securities, Current [Abstract]
Maturity securities Amortized cost	41	36
Maturity securities Gross unrealized gains (losses)
Maturity securities Estimated fair value	41	36
Commercial bonds [Member] | Short-term [Member]
Marketable Securities, Current [Abstract]
Maturity securities Amortized cost	1,823	2,118
Maturity securities Gross unrealized gains (losses)	(1)
Maturity securities Estimated fair value	$ 1,822	$ 2,118

Marketable Securities (Detail34

Marketable Securities (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Marketable Securities (Textual)
Percentage of ownership interest	7.90%
Cost of securities	$ 595	$ 595	$ 595
Marketable securities	$ 2,151	$ 530
Maximum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.87%	1.80%
Minimum [Member]
Marketable Securities (Textual)
Yield to cost rates	1.30%	0.96%

Long-Term Deposits (Details)

Long-Term Deposits (Details) - USD ($) $ in Thousands		Aug. 31, 2017	Aug. 31, 2016
Short-Term Deposits/ Long-Term Deposits [Abstract]
Bank deposits	[1]	$ 16,230	$ 11,038
Lease car deposits		1	4
Investment		1	1
Total long term deposits and investment		$ 16,232	$ 11,043
[1]	Represents U.S. dollar bank deposits which carry fixed annual interest rates between 2.06% to 2.56%, with maturities of more than one year from balance sheet date. The latest maturity date is during the year ending August 31, 2019.

Long-Term Deposits (Details Tex

Long-Term Deposits (Details Textual)	12 Months Ended
	Aug. 31, 2017
Long Term Deposits (Textual)
Maturity date	Aug. 31, 2019
Maximum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	2.56%
Minimum [Member]
Long Term Deposits (Textual)
Bank deposits interest rate	2.06%

Accounts Payable and Accrued 37

Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Aug. 31, 2017	Aug. 31, 2016
Accounts Payable and Accrued Expenses [Abstract]
Accounts payable	$ 571	$ 365
Payroll and related accruals	97	66
Institutions	228
Accrued liabilities	1,593	980
Other	227
Total accounts payable and accrued expenses	$ 2,716	$ 1,411

Commitments (Details)

Commitments (Details) $ in Thousands

May 03, 2017shares

Oct. 01, 2016

Jun. 13, 2016USD ($)

Jun. 13, 2016EUR (€)

May 11, 2016USD ($)

Mar. 03, 2016USD ($)

Mar. 03, 2016CHF (SFr)

Mar. 03, 2014USD ($)

Feb. 21, 2017USD ($)

Jul. 24, 2016USD ($)

Mar. 31, 2011USD ($)shares

Aug. 31, 2017USD ($)shares

Aug. 31, 2017EUR (€)shares

Aug. 31, 2017CHF (SFr)shares

Aug. 31, 2016USD ($)

Aug. 31, 2015USD ($)

Feb. 15, 2011

Long-term Purchase Commitment [Line Items]

Commitments for consulting services

$ 594

Options granted | shares

808,783

808,783

808,783

Total revenue

$ 2,194

Research and development expense

10,281

$ 7,709

$ 4,781

Office Building [Member]

Long-term Purchase Commitment [Line Items]

Operating lease term

60 months

Lease expenses

$ 32

$ 23

$ 23

Lessee, description

The annual lease payment will be New Israeli Shekel ("NIS") 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and will be linked to the increase in the Israeli consumer price index ("CPI") (as of August 31, 2017, the future lease payments until the expiration of the lease agreement will be $143, based on the exchange rate as of August 31, 2017).

The annual lease payment will be New Israeli Shekel ("NIS") 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and will be linked to the increase in the Israeli consumer price index ("CPI") (as of August 31, 2017, the future lease payments until the expiration of the lease agreement will be $143, based on the exchange rate as of August 31, 2017).

The annual lease payment will be New Israeli Shekel ("NIS") 119,000 ($33) from October 2016 through September 2018 and NIS 132,000 ($37) from October 2018 through September 2021, and will be linked to the increase in the Israeli consumer price index ("CPI") (as of August 31, 2017, the future lease payments until the expiration of the lease agreement will be $143, based on the exchange rate as of August 31, 2017).

Bio Jerusalem [Member]

Long-term Purchase Commitment [Line Items]

Royalty percentage

4.00%

Royalty percentage maximum percentage of grants received

100.00%

100.00%

100.00%

Grants receivable

$ 65

Grants received

2,653

Royalty expenses

$ 47

Israel Innovation Authority [Member]

Long-term Purchase Commitment [Line Items]

Royalty percentage

3.50%

Total revenue

$ 2,653

Research and development expense

49

Royalty expenses

$ 140

Israel Innovation Authority [Member] | Minimum [Member]

Long-term Purchase Commitment [Line Items]

Royalty percentage

100.00%

Israel Innovation Authority [Member] | Maximum [Member]

Long-term Purchase Commitment [Line Items]

Royalty percentage

150.00%

Entera Bio [Member] | D.N.A. [Member]

Long-term Purchase Commitment [Line Items]

Ownership percentage retained

3.00%

Ordinary shares received | shares

4,202,334

Royalty percentage

3.00%

8.00%

Cost method investment

$ 1

Advisor [Member]

Long-term Purchase Commitment [Line Items]

Commitments for consulting services

$ 958

Capitalized cost

$ 160

Shares issued for services | shares

10,000

2,500

2,500

2,500

Grants received

$ 20

First Master Service Agreement [Member]

Long-term Purchase Commitment [Line Items]

Commitments for consulting services

$ 1,283

$ 952

1,163

Commitments for bonus payments upon achieving certain milestones

600

Third Master Service Agreement [Member]

Long-term Purchase Commitment [Line Items]

Commitments for consulting services

$ 311

175

Fourth Master Service Agreement [Member]

Long-term Purchase Commitment [Line Items]

Total revenue

$ 2,726

€ 2,360,000

Non refundable revenue

878

€ 800,000

Proposal Agreement [Member]

Long-term Purchase Commitment [Line Items]

Development and production on capsules

$ 1,027

SFr 1,000,000

615

SFr 605,000

General Technical Agreement [Member]

Long-term Purchase Commitment [Line Items]

Development and production on capsules

$ 4,300

$ 3,327

Stockholders' Equity (Details)

Stockholders' Equity (Details) - Warrant [Member] - $ / shares	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Warrants
Warrants outstanding	615,338	981,940	953,369
Issued			28,571
Exercised	(248,882)	(331,054)
Expired	(199,814)	(35,548)
Warrants outstanding	166,642	615,338	981,940
Warrants exercisable	166,642	615,338	981,496
Weighted-Average Exercise Price
Weighted-Average Exercise Price, Warrants outstanding	$ 5.92	$ 5.29	$ 5.15
Issued			10
Exercised	4.99	4.04
Expired	6.82	6
Weighted-Average Exercise Price, Warrants outstanding	6.46	5.92	5.29
Weighted-Average Exercise Price, Warrants exercisable	$ 6.46	$ 5.92	$ 5.29

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	Dec. 28, 2015	Jun. 30, 2015	Jun. 05, 2015	Apr. 02, 2015	Nov. 03, 2014	Oct. 31, 2014	Oct. 31, 2017	Sep. 30, 2017	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Stockholders' Equity (Textual)
Net proceeds from offering									$ 25	$ 10,594	$ 9,713
Common stock offering price	$ 49,500								$ 25	$ 10,594
Percentage of commission				3.00%
Purchase of warrants, Shares									166,642
Number of shares sold									2,970
Subsequent Event [Member]
Stockholders' Equity (Textual)
Number of shares sold							453,919	453,919
Stock Purchase Agreement [Member]
Stockholders' Equity (Textual)
Aggregate of common stock, shares					696,378
Purchase price per share					$ 7.18
Net proceeds from offering					$ 4,833	$ 5,000
Placement agent's commissions					$ 150
Common stock offering price				$ 25,000
Engagement Letter [Member]
Stockholders' Equity (Textual)
Aggregate of common stock, shares			714,286
Purchase price per share			$ 10
Net proceeds from offering		$ 4,880
Placement agent's commissions		$ 478
Common stock price			$ 7.50
Sale of stock, description			The Overallotment Right shall be exercisable beginning December 10, 2015, and shall remain exercisable until December 10, 2016. Pursuant to the Engagement Letter, HCW received, for its services in the June 2015 Offering, a fee equal to 7% of the gross proceeds raised in the June 2015 Offering and an expense allowance of 1% of the gross proceeds raised in the June 2015 Offering.
Purchase of warrants, Shares		28,571
Exercise price		$ 10
Exercisable expiration period		3 years
Private Placement [Member]
Stockholders' Equity (Textual)
Aggregate of common stock, shares	1,155,367
Maximum [Member]
Stockholders' Equity (Textual)
Exercise price									$ 10
Investment warrants expiration date									Jun. 10, 2018
Minimum [Member]
Stockholders' Equity (Textual)
Exercise price									$ 3.7656
Investment warrants expiration date									Nov. 2, 2017

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - Options [Member]	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)		10 years
Expected stock price volatility (%)		80.46%
Risk free interest rate (%)		2.24%
Expected dividend yield (%)	0.00%	0.00%
Maximum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)	10 years
Expected stock price volatility (%)	77.29%
Risk free interest rate (%)	2.47%
Minimum [Member]
Schedule of fair value of each option grant using the Black Scholes option-pricing model
Expected option life (years)	5 years
Expected stock price volatility (%)	74.15%
Risk free interest rate (%)	1.83%

Stock-Based Compensation (Det42

Stock-Based Compensation (Details 1) - $ / shares	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Changes during the year:
Granted	808,783
Employees and Directors [Member]
Number of options
Options outstanding at beginning of year	904,234	904,234	908,901
Changes during the year:
Granted	427,497
Forfeited			(3,297)
Expired	(59,282)
Exercised	63,900		(1,370)
Options outstanding at end of year	1,208,549	904,234	904,234
Options exercisable at end of year	808,783	904,234	883,234
Weighted average fair value of options granted during the year	$ 4.75
Weighted average exercise price
Options outstanding at beginning of year	6.75	6.75	6.75
Changes during the year:
Granted	7.51
Forfeited			6
Expired	10.27
Exercised	5		6
Options outstanding at end of year	$ 6.94	$ 6.75	$ 6.75

Stock-Based Compensation (Det43

Stock-Based Compensation (Details 2) $ / shares in Units, $ in Thousands	12 Months Ended
	Aug. 31, 2017USD ($)$ / sharesshares
Employees and Directors [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	1,208,549
Weighted Average Remaining Contractual Life	5 years 11 months 4 days
Weighted average exercise price | $ / shares	$ 6.94
Aggregate intrinsic value | $	$ 2,484,266
Employees and Directors [Member] | 1.00 to 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	442,671
Weighted Average Remaining Contractual Life	3 years 11 months 1 day
Weighted average exercise price | $ / shares	$ 4.74
Aggregate intrinsic value | $	$ 1,730,803
Employees and Directors [Member] | 6.48 to 7.88 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	635,959
Weighted Average Remaining Contractual Life	7 years 1 month 2 days
Weighted average exercise price | $ / shares	$ 7.47
Aggregate intrinsic value | $	$ 751,863
Employees and Directors [Member] | 8.57 to 12.45 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	129,919
Weighted Average Remaining Contractual Life	7 years 1 month 13 days
Weighted average exercise price | $ / shares	$ 11.85
Aggregate intrinsic value | $	$ 1,600
Non-employees [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	55,486
Weighted Average Remaining Contractual Life	8 years 1 month 2 days
Weighted average exercise price | $ / shares	$ 6.71
Aggregate intrinsic value | $	$ 111,353
Non-employees [Member] | 6.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	37,152
Weighted Average Remaining Contractual Life	9 years 6 months 21 days
Weighted average exercise price | $ / shares	$ 6
Aggregate intrinsic value | $	$ 98,453
Non-employees [Member] | 7.36 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	10,000
Weighted Average Remaining Contractual Life	8 years 2 months 19 days
Weighted average exercise price | $ / shares	$ 7.36
Aggregate intrinsic value | $	$ 12,900
Non-employees [Member] | 9.12 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number outstanding | shares	8,334
Weighted Average Remaining Contractual Life	1 year 4 months 9 days
Weighted average exercise price | $ / shares	$ 9.12
Aggregate intrinsic value | $

Stock-Based Compensation (Det44

Stock-Based Compensation (Details 3) - $ / shares	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Changes during the year:
Granted	808,783
Non Employees [Member]
Number of options
Options outstanding at beginning of year	29,668	40,286	62,221
Changes during the year:
Granted	37,152	22,000
Exercised		(18,718)
Forfeited		(9,000)
Expired	(11,334)	(4,900)	(21,935)
Options outstanding at end of year	55,486	29,668	40,286
Options exercisable at end of year	27,622	29,668	36,119
Weighted average exercise price
Options outstanding at beginning of year	$ 8.35	$ 7.29	$ 7.13
Changes In Weighted Average Exercise Price During Year [Abstract]
Granted	6	7.36
Exercised		6
Forfeited		7.36
Expired	8.65	6	6.82
Options outstanding at end of year	$ 6.71	$ 8.35	$ 7.29

Stock-Based Compensation (Det45

Stock-Based Compensation (Details 4) - Restricted Stock Units (RSUs) [Member] - Employees And Directors [Member] - shares	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested at the beginning of period	201,669	313,216
Granted	178,120	1,000	346,704
Vested and issued	(159,353)	(101,459)	(33,488)
Forfeited	(22,160)	(11,088)
Outstanding at the end of the period	198,276	201,669	313,216
Vested and unissued (see notes 8a, 8c and 8j(2))	164,636	152,656	72,808

Stock-Based Compensation (Det46

Stock-Based Compensation (Details Textual) $ / shares in Units, $ in Thousands

Feb. 09, 2017USD ($)$ / sharesshares

Nov. 01, 2016USD ($)Installments$ / sharesshares

Aug. 03, 2016shares

Jan. 31, 2016shares

Dec. 01, 2015shares

Feb. 28, 2015Installmentsshares

Feb. 23, 2015USD ($)Installments$ / sharesshares

Dec. 31, 2014Installmentsshares

Nov. 13, 2014USD ($)Installments$ / sharesshares

Jul. 19, 2017USD ($)$ / sharesshares

Jun. 30, 2017USD ($)Installments$ / sharesshares

Mar. 20, 2017USD ($)Installments$ / sharesshares

Dec. 31, 2016Installmentsshares

Aug. 24, 2016shares

Dec. 31, 2015Installmentsshares

Nov. 19, 2015$ / sharesshares

Mar. 31, 2015Installmentsshares

Aug. 31, 2017USD ($)$ / sharesshares

Aug. 31, 2016USD ($)$ / sharesshares

Aug. 31, 2015USD ($)$ / sharesshares

Aug. 31, 2014shares

Apr. 30, 2017shares

Stock-Based Compensation (Textual)

Options granted

808,783

Stock based compensation | $

$ 1,575

$ 634

$ 1,347

Intrinsic value of options exercised | $

$ 85

CEO [Member]

Stock-Based Compensation (Textual)

Number of installments | Installments

3

Options granted

147,000

Options granted, exercise price | $ / shares

$ 7.77

Fair value of options granted | $

$ 585

Number of options to vest each installment

49,000

Expiration date

Jun. 30, 2027

Expected dividend yield

0.00%

Expected volatility

75.00%

Risk-free interest rate

2.34%

Expected term

10 years

Employees and Directors [Member]

Stock-Based Compensation (Textual)

Maximum term of the options

10 years

Options granted

427,497

Options granted, exercise price | $ / shares

$ 7.51

Expected term

2 years 18 days

Stock based compensation | $

$ 451

$ 14

$ 278

Intrinsic value of options exercised | $

Unrecognized compensation expense | $

$ 1,579

RSU forfeited

Non Employees [Member]

Stock-Based Compensation (Textual)

Options granted

37,152

22,000

Options granted, exercise price | $ / shares

$ 6

$ 7.36

Stock based compensation | $

$ 59

$ 102

$ 3

Intrinsic value of options exercised | $

37

Amended and Restated 2008 Stock Incentive Plan [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

2,400,000

December 31, 2019 [Member] | CEO [Member]

Stock-Based Compensation (Textual)

Quoted closing market share price | $ / shares

$ 12.50

December 31, 2018 [Member] | CEO [Member]

Stock-Based Compensation (Textual)

Quoted closing market share price | $ / shares

9.50

December 31, 2017 [Member] | CEO [Member]

Stock-Based Compensation (Textual)

Quoted closing market share price | $ / shares

$ 8

Restricted stock units [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

70,000

Number of installments | Installments

19

Stock based compensation | $

$ 1,064

$ 518

1,066

Unrecognized compensation expense | $

$ 88

Debt instrument, description

18 equal monthly installments of 1,500 shares each, commencing November 30, 2016 and 17,000 shares on each of April 30, 2017 and 2018.

Restricted stock units [Member] | One installment

Stock-Based Compensation (Textual)

Options granted

9,000

CEO and CSO [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

9,788

Vested and outstanding RSUs

9,788

CEO and CSO [Member] | Restricted stock units [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

159,696

19,576

79,848

Number of installments | Installments

23

2

2

Options vested

9,788

9,788

Vested and outstanding RSUs

79,848

Fair value of restricted stock units | $

$ 728

$ 135

Quoted closing market share price | $ / shares

$ 4.56

$ 6.90

CEO and CSO [Member] | Restricted stock units [Member] | One installment

Stock-Based Compensation (Textual)

Number of installments | Installments

1

Options vested

13,308

CEO and CSO [Member] | Restricted stock units [Member] | 22 equal monthly installments

Stock-Based Compensation (Textual)

Number of installments | Installments

22

Options vested

6,654

Board of Directors [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

10,872

Fair value of restricted stock units | $

$ 75

Quoted closing market share price | $ / shares

$ 6.90

Options granted

56,773

Options granted, exercise price | $ / shares

$ 7.77

Number of vesting installments | Installments

4

Fair value of options granted | $

$ 294

Expiration date

Jun. 30, 2027

Expected dividend yield

0.00%

Expected volatility

74.15%

Risk-free interest rate

2.14%

Expected term

6 years 2 months 5 days

Unrecognized compensation expense | $

Board of Directors [Member] | Non Employees [Member]

Stock-Based Compensation (Textual)

Options granted

27,622

Expected term

1 year 6 months

Unrecognized compensation expense | $

$ 196

Board of Directors [Member] | December 31, 2019 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

15,591

Board of Directors [Member] | December 31, 2018 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

15,591

Board of Directors [Member] | December 31, 2017 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

15,591

Board of Directors [Member] | December 31, 2020 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

10,000

Board of Directors [Member] | Restricted stock units [Member] | Second Installment [Member]

Stock-Based Compensation (Textual)

RSU vested

22,179

RSU forfeited

11,088

Subsidiary Employees Three [Member]

Stock-Based Compensation (Textual)

Options granted

20,001

38,901

Options granted, exercise price | $ / shares

$ 8.57

$ 7.77

Fair value of options granted | $

$ 113

$ 200

Expiration date

Jun. 30, 2027

Expected dividend yield

0.00%

0.00%

Expected volatility

74.65%

74.77%

Risk-free interest rate

1.83%

1.89%

Expected term

6 years

6 years

Subsidiary Employees Three [Member] | Restricted stock units [Member]

Stock-Based Compensation (Textual)

Share-based Compensation awards granted

63,216

Fair value of restricted stock units | $

$ 288

Quoted closing market share price | $ / shares

$ 4.56

Subsidiary Employees Three [Member] | Restricted stock units [Member] | One installment

Stock-Based Compensation (Textual)

Number of shares reserved for grant

17,000

Number of installments | Installments

1

Options vested

5,268

Fair value of restricted stock units | $

$ 463

Quoted closing market share price | $ / shares

$ 6.62

Options granted

1,500

Subsidiary Employees Three [Member] | Restricted stock units [Member] | 22 equal monthly installments

Stock-Based Compensation (Textual)

Number of installments | Installments

22

Options vested

2,634

Board of Directors Four [Member]

Stock-Based Compensation (Textual)

Options granted

27,731

Options granted, exercise price | $ / shares

$ 6.23

Fair value of options granted | $

$ 45

Expiration date

Feb. 9, 2027

Expected dividend yield

0.00%

Expected volatility

77.29%

Risk-free interest rate

1.88%

Expected term

5 years

Options vested expiration description

(a) 16,337 options at an exercise price of $1 per share (lower than the traded market price of $6.23 on the date of grant). The fair value of these options on the date of grant was $90, using the Black Scholes option-pricing model and was based on the following assumptions: Stock price of $6.23; dividend yield of 0% for all years; expected volatility of 77.29%; risk-free interest rates of 1.88%; and expected term of 5 years; (b) 11,394 options at an exercise price of $6.23 per share (equivalent to the traded market price on the date of grant).

Board of Directors Four [Member] | Restricted stock units [Member]

Stock-Based Compensation (Textual)

Number of shares reserved for grant

88,712

Number of installments | Installments

3

2

2

Options vested

44,356

44,356

Fair value of restricted stock units | $

$ 405

Quoted closing market share price | $ / shares

$ 4.56

Options granted

67,092

Options granted, exercise price | $ / shares

$ 7.77

Fair value of options granted | $

$ 344

Expiration date

Jun. 30, 2027

Expected dividend yield

0.00%

Expected volatility

74.77%

Risk-free interest rate

1.89%

Expected term

6 years

RSUs granted to each director

22,178

Consultants [Member]

Stock-Based Compensation (Textual)

Options vested

3,000

Options granted

12,000

37,152

Options granted, exercise price | $ / shares

$ 6

Number of vesting installments | Installments

24

Fair value of options granted | $

$ 261

Expiration date

Mar. 20, 2027

Expected dividend yield

0.00%

Expected volatility

73.62%

Risk-free interest rate

2.12%

Expected term

9 years 7 months 6 days

Unvested options forfeited

9,000

Options vested expiration description

In addition, the expiration date of the 3,000 vested options was updated to November 3, 2016 (3 months following the termination date of the agreement).

Consultants [Member] | One installment

Stock-Based Compensation (Textual)

Options granted

1,548

Fair value of options granted | $

$ 177

Two Consultants [Member]

Stock-Based Compensation (Textual)

Options granted

22,000

Options granted, exercise price | $ / shares

$ 7.36

Expiration date

Nov. 19, 2025

Two Consultants [Member] | One installment

Stock-Based Compensation (Textual)

Options vested

10,000

Two Consultants [Member] | Twelve Equal Installments [Member]

Stock-Based Compensation (Textual)

Options vested

12,000

CSO [Member]

Stock-Based Compensation (Textual)

Options granted, exercise price | $ / shares

$ 7.77

Expiration date

Jun. 30, 2027

Expected dividend yield

0.00%

Expected volatility

74.77%

Risk-free interest rate

1.89%

Expected term

6 years

Options vested expiration description

(a) 75,000 RSUs representing a right to receive shares of the Company's common stock which vested immediately, have an exercise price of $0.012 per share of common stock and expire on June 30, 2027. The total fair value of these RSUs on the date of grant was $582, using the quoted closing market share price of $7.77 on the Nasdaq Capital Market on the date of grant; The shares of common stock underlying the RSUs will be issued upon request of the grantee. As of August 31, 2017, none of these RSUs were exercised. (b) options to purchase an aggregate of 69,999 shares of the Company, at an exercise price of $7.77 per share (equivalent to the traded market price on the date of grant).

CSO [Member] | December 31, 2019 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

23,333

CSO [Member] | December 31, 2018 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

23,333

CSO [Member] | December 31, 2017 [Member]

Stock-Based Compensation (Textual)

Number of options to vest each installment

23,333

Financial Income and Expenses47

Financial Income and Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Financial income
Income from interest on deposits	$ 657	$ 378	$ 160
Exchange rate differences	7
Income from interest on corporate bonds	128	96	8
Financial income	$ 792	$ 474	$ 168

Financial Income and Expenses48

Financial Income and Expenses (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Financial expenses
Exchange rate differences	$ 17	$ 17	$ 3
Bank commissions	6	11	9
Other	78	65	6
Financial expenses	$ 101	$ 93	$ 18

Taxes on Income (Details)

Taxes on Income (Details) - USD ($) $ in Thousands	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Schedule of deferred income taxes
Net operating loss carryforward	$ 9,253	$ 9,219	$ 5,750
Research and development expenses	2,046		906
Less - valuation allowance	(11,299)	(9,219)	(6,656)
Net deferred tax assets

Taxes on Income (Details 1)

Taxes on Income (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Loss before taxes on income:
U.S.	$ 1,115	$ 959	$ 1,226
Outside U.S.	8,965	8,670	6,007
LOSS BEFORE TAXES ON INCOME	(10,080)	(9,629)	(7,233)
Current:
U.S.		(15)
Outside U.S.	400	1,350	(1)
Income tax expenses (benefit), Total	$ 400	$ 1,335	$ (1)

Taxes on Income (Details 2)

Taxes on Income (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Schedule of reconciliation of income taxes
Loss before income taxes as reported in the consolidated statement of comprehensive loss	$ (10,080)	$ (9,629)	$ (7,233)
Statutory tax benefit	(3,528)	(3,370)	(2,531)
Increase (decrease) in income taxes resulting from:
Change in the balance of the valuation allowance for deferred tax	2,080	2,563	1,599
Disallowable deductions	327	167	422
Influence of different tax rates and changes in tax rates applicable to the Subsidiary	1,121	640	510
Withholding tax, see note 10c above	400	1,350
Uncertain tax position		(15)	(1)
TAXES ON INCOME (TAX BENEFIT) (note 10c)	$ 400	$ 1,335	$ (1)

Taxes on Income (Details 3)

Taxes on Income (Details 3) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Schedule of unrecognized tax benefits activity
Balance at Beginning of Year	$ 11	$ 26	$ 27
Decrease in uncertain tax positions for the current year		(15)	(1)
Balance at End of Year	$ 11	$ 11	$ 26

Taxes on Income (Details 4)

Taxes on Income (Details 4) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Balance at beginning of period	$ 9,219	$ 6,656
Balance at end of period	11,299	9,219	$ 6,656
Year ended August 31, 2017 [Member]
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Balance at beginning of period	9,219	6,656
Additions	2,080
Balance at end of period	11,299	9,219	6,656
Year ended August 31, 2016 [Member]
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Balance at beginning of period	$ 9,219	6,656
Additions		2,563
Balance at end of period		9,219	6,656
Year ended August 31, 2015 [Member]
Deferred Tax Assets, Net of Valuation Allowance [Abstract]
Balance at beginning of period		$ 6,656	5,578
Additions			1,078
Balance at end of period			$ 6,656

Taxes on Income (Details Textua

Taxes on Income (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
Taxes on income (Textual)
Carryforward tax losses expire	5 years
Net loss carryforward will expire years, Description	2025 through 2037.
Taxes on income	$ 400	$ 1,335	$ (1)
Corporate taxation in the U.S. [Member]
Taxes on income (Textual)
Corporate tax rate	35.00%
Accumulated tax loss carryforward	$ 10,060	$ 8,945
Carryforward tax losses expire	20 years
Net loss carryforward will expire years, Description	2013 through 2017.
Corporate taxation in Israel [Member]
Taxes on income (Textual)
Corporate tax rate	24.00%	25.00%	26.50%
Accumulated tax loss carryforward	$ 26,881	$ 18,580
Net loss carryforward will expire years, Description	2013 through 2017.

Related Parties - Transaction55

Related Parties - Transactions (Details) - USD ($) $ in Thousands	Aug. 31, 2017	Aug. 31, 2016
Related Party Transaction [Line Items]
Accounts payable and accrued expenses - KNRY		$ 48
KNRY [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued expenses - KNRY		$ 48

Related Parties - Transaction56

Related Parties - Transactions (Details 1) - USD ($)	12 Months Ended
	Aug. 31, 2017	Aug. 31, 2016	Aug. 31, 2015
KNRY [Member]
Related Party Transaction [Line Items]
Expenses to related parties	$ 868	$ 839	$ 586

Related Parties - Transaction57

Related Parties - Transactions (Details Textual) $ in Thousands	Jul. 01, 2008	Aug. 31, 2017USD ($)	Aug. 31, 2017ILS (₪)	Aug. 31, 2016USD ($)	Aug. 31, 2015USD ($)
Related Parties Transactions (Textual)
Directors fees		$ 100		$ 92	$ 47
KNRY [Member]
Related Parties Transactions (Textual)
Consulting agreements, description	The Consulting Agreements are both terminable by either party upon 60 days prior written notice. The Consulting Agreements, as amended, provide that KNRY will be reimbursed for reasonable expenses incurred in connection with performance of the Consulting Agreements and that the monthly consulting fee paid to the CEO and the CSO is NIS 127,570 ($35) and NIS 80,454 ($22), respectively.
CEO [Member]
Related Parties Transactions (Textual)
Monthly consulting fee		35	₪ 127,570
CSO [Member]
Related Parties Transactions (Textual)
Monthly consulting fee		$ 22	₪ 80,454